NCT01877005View on ClinicalTrials.gov

A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 4, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 12, 2018

Conditions
Hodgkin's Lymphoma
Interventions
DRUG

Ruxolitinib

Trial Locations (10)

5530

Université Catholique de Louvain Mont Godinne, Yvoir

10200

UCL Louvain St Luc, Brussels

14000

Chu Cote de Nacre, Caen

21000

Chu Dijon, Dijon

44093

CHU de Nantes, Hotel Dieu, Nantes

59037

Chru de Lille, Lille

69373

Centre Leon Berard, Lyon

69495

Centre Hospitalier Lyon Sud, Lyon

76038

Centre Henri Becquerel, Rouen

94010

Hopital Henri Mondor, Créteil

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

The Lymphoma Academic Research Organisation

OTHER

NCT01877005 - A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter